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Objective Heavy post-transplant immunosuppression may contribute to long-term immunosuppression dependence by 
subverting tolerogenic mechanisms; thus, we sought to determine if this undesirable consequence could be mitigated by 
pretrunsplant lymphoid depletion and miuimalistic post-transplant monotherupy. 
Study design Lymphoid depletion in 17 nnselected pediatric recipients of live (n = 14) or deceased donor kidneys (n = 3) 
was accomplished with antithYlllocyte globulin (ATG) (n = 8) or alemtuzumab (11 = 9). Tacrolilllus was begun post-
transplantation with subsequent lengthening of intervals between doses (spaced weaning). Maintenance immunosuppression, 
morbidity, gruft function, and patient/graft survival were collated. 
Results Stel"Oids were added temporarily to treat rejection in two patients (both ATG subgroup) or to treat hemolytic anemia 
in two others. After 16 to 31 months (mean 22). patient and graft sun-ivai was 100% and 94%, respectively. The only graft loss 
was in a nonweaned noncompliant recipient. In the other 16, serum creatinine was 0.85 ± 0.35 mg/dL and creatinine clearance 
was 90.8 ± 22.1mU1.73 1112. All 16 patients are on mono therapy (15 tacrolimus, one sirolimus), and 14 receive every other 
day or J times per week doses. There were no wound or other infections. Two patients developed insulin-dependent diabetes. 
Conclusion The strategy of lymphoid depletion and minimum post-transplant inmlUnosuppression appears safe and effec-
tive for pediatric ludney recipients. (J Pediatr 2006:148:813-8) 
U ntil the late 1960s, renal transplantation in pediatric. patients was a controversial service that was systematically provided in only a few centers. 1-4 Numerous ethical issues were raised at the outset, including risk to live donors, effects on family 
unity, mental health of well siblings, and doubts about the long-term prognosis.s Some of these anxieties have been 
relieved with the passage of time. For example, complications associated with heavy steroid use have been progressively 
circumvented with better adjunct6 and/or baseline drugs?-13 However, chronic immunodepression per se and drug-speci1ic side 
effects (eg, nephrotoxicity) have remained the principal threats to the quality and duration of life of the pediatric recipient. 14- I6 
We report here an experience in 17 pediatric kidney recipients in whom the burden oflong-term immunosuppression was 
lightened with a treatment regimen designed to avoid acute rejection while interfering 
minimally with natural tolerogenic mechanisms.17 One principle of the strategy consisted 
of lymphoid depletion before renal allograft revascularization. In the first eight patients, 
the lymphoid depletion was done with antithymocyte globulin (ATG; Thymoglobu-
linR).18 In the next nine patients, alemtuzumab (Campath-lHIO)19-23 was used. The 
second therapeutic principle consisted of the use of the least amount of post-transplant 
immunosuppression consistent with stable graft function. This was accomplished by 
beginning the postoperative course on tacrolimus mono therapy with subsequent attempts 
to reduce the frequency of dosing (spaced dose weaning). 
METHODS 
Populations 
Between May 2003 and July 2004, 17 of 18 consecutive kidney-alone recipients at 
the Children's Hospital of Pittsburgh (CHP) were treated with the tolerogenic strategy. 
In the single exclusion, the lymphoid depletion was inadvertently omitted. Two subgroups 
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Table I. Donor and recipient population(s) 
All ATG Alemtuzumab 
n 17 8 9 
Case accrual 5103 to 7/04 5/03 to 12103 1/04 to 7104 
Mean recipient 9.4 ± 6.S 8.6 ± 7.3 10.1 ± 6.1 
age (y) 
Recipient age I to 18 I to 18 I to 18 
range (y) 
Primary graft 15 (88%) 7 (87.5%) 8 (89%) 
Live donor 14 (82%) 6 (75%) 8 (89%) 
Donor age (y) 36.2 ± 9.0 37.0 ± 7.6 35.6 ± 10.5 
HLA mismatch 2.6 ± 1.2 2.3 ± 1.7 2.9 ± 0.6 
(of 6) 
Deceased donor 23.4 ± 9.3 18.1 ± 1.8 34 
CIT (HR) 
were defined by the agent used for lymphoid depletion, ie, 
ATG Cn = 8) or alemtuzumab Cn = 9). There were no 
differences between the two groups in the donor and recipient 
demographics and risk factors (Table I). All 17 grafts f1.mc-
tioned well at the outset. 
Immunosuppression 
LYMPHOID DEPLETION. The first eight patients were infused 
with 5 mg/kg rabbit ATG. In the six recipients of live donor 
kidneys of this group, the ATG dose was divided. The first 3 
mg/kg were infused slowly thrqughout the night preceding 
operation, whereas an additional 2 mg/kg were given after the 
induction of anesthesia. The two cadaveric organ recipients 
had a single 5 mg/kg infusion. For the nine patients treated 
after December 2003,0.4 to 0.5 mglkg alemtuzumab (Cam-
path-1H®) were substituted for the ATG. The alemtuzumab 
was infused overa 2- to 4-hour interval that included periods 
following the induction of anesthesia. 
In all 17 patients, two doses of 10- to 15-mg/kg intra-
venous methylprednisolone were administered to prevent 
ATG- or alemtuzumab-induced cytokine reactions. The first 
steroid infusion coincided with the antibody infusion, and 
the second was given during performance of the arterial 
anastomosis. 
TACROLIMUS. Twice daily monotherapy was started orally on 
postoperative day 1, with tacrolimus target trough levels of 10 
ng/mL. Approximately 4 to 6 months after transplantation, 
the twice daily dosage was consolidated to a single daily dose, 
eg, 2 mg in the morning and evening were given as a 4-mg 
morning dose. Three to 6 months after this initial step, the 
interval between tacrolimus doses was lengthened to every 
other day or 3 times per week (Figure 1). 
All subsequent decisions about tacrolimus doses were 
based on what already had transpired in the individual case, 
with particular weight given to serum creatinine concentra-
tion and urinalysis. Steroids or other agents were not added to 
baseline mono therapy unless there was evidence of acute 
rejection (n = 2), or in two cases, for the treatment of 
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Figure I. Course of a 1S-year-old recipient of a maternal kidney. The 
patient was pretreated with ATG. The twice daily tucrolimus (Tac.) dose 
of S mg was consolidated to one 10 mg per day after 4 months. At 8.5 
months, the dose was spaced to every other day and has remained at that 
frequency for 20 months (top panel). Because serum creatinine and 
creatinine clearance have been stable throughout. there have been no 
biopsies or additional treatment (bottom two panels). 
hemolytic anemia. VVhen necessary, steroid therapy was tem-
porary, eg, a single bolus of methylprednisolone, or a 3- to 
5-day course of high-dose steroids that was rapidly weaned 
thereafter. Biopsies were obtained only for specific indications 
such as an increase in serum creatinine. 
Infection Prophylaxis and Monitoring 
The following long-standing practice on the kidney 
transplant service at the. CHP was not modified. Prophylaxis 
with trimethotrim sulfamethoxazole, nystatin, and oral val-
gancyclovir was administered for a minimum of 6 months. 
With transplantation from an Epstein Barr Virus (EBV) or 
Cytomegalo virus (CMV)-seropositive donor to an EBV- or 
CMV -negative recipient, the valgancyclovir prophylaxis was 
extended to 12 months and a single 100-mg/kg dose ofCMV 
immune globulin was administered on postoperative day l. 
Q1antitative EBV testing with polymerase chain reaction was 
done monthly for the first 6 months and every other month 
for the subsequent 6 months. Assays of CMV antigenemia 
were performed weekly for 3 months, every other week during 
months 3 to 6, then monthly out to 1 year. Screening for 
polyoma (BK) virus was done as clinically indicated. 
Institutional Review 
The immunosuppression strategy applied in the pe-
diatric renal recipients reported here was accepted in 2001 
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Table II. Results in the 16 patients with functioning grafts* 
All ATG Alemtuzumab 
(n 16) (n 7) (n 9) 
Follow-up months 22 ± 4.9 26 ± 2.S IS ± 2.6 
Creatinine 0.85 ± 0.35 0.96 ± 0.30 0.77 ± 0.38 
Creatinine clearance 90.8 ± 22.1 75.6 ± 12.5 102.5 ± 21.0 
Spaced dose weaning 14 (88%) 5 (71%) 9 (100%) 
Months to spaced dosing 11.1 ± 3.5 11.7 ± 3.8 9.9 ± 2.3 
Months since spaced dosing 10.5 ± 5.1 14.3 ± 5.4 8.4 ± 3.6 
Received post-transplant prednisone 3t 2t 1:1: 
Acute rejection I (6%) I (14%) 0 
Delayed graft function 0 0 0 
Patients biopsied 6 (38%) 3 (43%) 3 (33%) 
PTLD 0 0 0 
CMV 0 0 0 
Polyoma (BK) virus 0 0 0 
Post-transplant diabetes 2 (13%):1: 0 2 (22%):1: 
Autoimmune hemolytic anemia 2 (13%) I (14%) I (11%) 
*A 17'h patient who lost hergraft to noncompliance is described separately in the text. Including all 17. patientlgnft survival is 100%194%: 100%188% in the ATG subgroup (n = 
8) and 100%1100% in the a1emtuzumab subgroup (n = 9). 
tlncludes one patient treated for rejection in the ATG group and two patients (one in each group) treated with steroids for autoimmune hemolytic anemia. 
tIncludes one patient with voracious post-transplant appetite and obesity. 
as standard of care for adult kidney and other kinds of 
organ recipients by the University of Pittsburgh Institu-
tional Review Board (IRB), and by the Innovative Practices 
Committee and the Pharmacy and Therapeutics Commit-
tees of the University of Pittsburgh Medical Center. The 
strategy was approved by the foregoing committees as the 
standard of care for pediatric recipients of liver, intestinal, 
or multivisceral allografts as of July 2001.24 The institu-
tional approvals were extended to pediatric kidney recipi-
ents in 2003 after extensive experience in adult renal 
recipients.25-27 The off-label use of alemtuzumab, an 
FDA-approved drug, and of the doses of ATG, were 
sanctioned by the IRB and the other aforementioned over-
sight committees. Informed consent that included a full 
description of the regimen(s) was obtained from the par-
ent(s) or legal guardian(s). 
Support from federal granting agencies or commer-
cial sources was neither sought nor accepted. There were 
no blood drawings from pediatric recipients for any pur-
pose other than patient care. No attempt was made to use 
blood, biopsy, or other specimens to elucidate tolerogenic 
mechanisms or other matters. Adverse events, including 
those related to medication were recorded according to 
existing practices of the CHP organ transplantation ser-
vices. In compliance with federal statutes, data were ex-
tracted for retrospective analysis from the clinical records 
using an IRB-approved honest brokering system. The in-
stitutional oversight policies of the CHP, the University of 
Pittsburgh, and the University of Pittsburgh Medical Cen-
ter are fully compliant with all legal statutes and with the 
regulations of the United States Department of Health and 
Human Services.28 
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RESULTS 
Survival 
With a mean follow-up of 22 ± 4.9 months (range 16 
to 31), patient survival is 100% and graft survival is 94%. The 
one graft loss was of a cadaver kidney in an 18-year-old 
pre-sensitized female (25% Panel Reactive Antibody [PRA], 
negative crossmatch) who was pretreated with ATG before 
undergoing retransplantation and who never underwent 
spaced weaning. Because of a slowly rising serum creatinine 
(to 1.6 mg/dL), the patient had a biopsy at 6 months that was 
diagnosed as pylonephritis (gram negative rods) and was 
treated with intravenous antibiotics. Two other late biopsies 
revealed rejection. She did not comply with subsequent fol-
low-up, was exposed to pregnancy risk while truant from her 
family and healthcare team, and lost her kidney after 20.5 
months. Further analysis (Table II) was confined to the other 
16 cases. 
Weaning 
As of November 2005, all 16 patients with functioning 
kidneys (Table II) are being treated with a single immuno-
suppressive drug: tacrolimus (n = 15) or sirolimus (n = 1). 
Fourteen of the 16 are on spaced doses (Figure 2). Five (71%) 
of the seven ATG-treated patients have been on every other 
day or 3 times per week doses of tacrolimus mono therapy for 
14.3 ± 5.4 months following the post-transplant institution 
of spaced dose schedules 11.7 ± 3.8 months postoperatively. 
The other two ATG-treated patients are on daily tacrolimus 
Cn = 1) or sirolimus Cn = 1). 
All nine alemtuzumab-treated patients have been on 
every other day or 3 times weekly tacrolimus doses for 8.4 ± 
815 
0% 
Daily mono-
therapy 
12% 
Spaced 
dose 
therapy 
88% 
Figure 2. Clment immunosuppression at a mean tallow-up of 22 ± 4.9 
months in 16 patients with functioning kidneys. Of the 14 patients on 
spaced-weaning (88%), 11 have doses every other day and three are on a 3 
times per week (Monday, Wednesday, Friday) schedule. 
3.6 months following the institution of dosing 9.9 :± 2.3 
months post-transplantation. 
Rejection and Graft Function 
The incidence of rejection before weaning was higher 
with the use of ATG compared with alemtuzumab (Table II). 
All of the six biopsies from the 16 patients with currently 
functioning grafts (one per each patient after 7 to 240 days 
after transplant, mean 73 :± 100) were obtained before the 
onset of spaced weaning. One of the biopsies had mild rejec-
tion that was treated with a bolus of prednisone. Two of the 
six specimens had unequivocal evidence of tubular vacuoliza-
tion, connoting drug toxicity. There were no examples of the 
focal segmental glomerulosclerosis described by Bartosh et al29 in 
one of their four pediatric recipients treated with alemtu-
zumab in a different strategy, nor was there any early or late 
evidence of a nephrotic syndrome. 
The incidence of clinical rejection after the start of 
weaning has been zero in both the ATG and alemtuzumab 
groups. In the 16 patients with functioning kidneys, the 
mean serum creatinine is 0.85 ± 0.35 mg/dL, with a mean 
calculated creatinine clearance of90.8 :± 22.1 mLl1.73 m2 
(Table II). Only two of the 16 patients are receiving any 
hypertensive drugs; both were 18 years of age and had been 
on multiple agents for several years before transplantation. 
One of these patients is currently receiving twice daily 
doses of nifedipine (extended release). The other is receiv-
ing twice daily doses of 60 mg nifedipine and one O.l-mg 
dose per day of clonidine. 
Infections 
There were no wound or systemic infectious complica-
tions in the 17 patients (including the noncompliant patient). 
Despite transplantation from CMV -positive donors to sero-
negative recipients in nine patients (53%), there were no 
examples of CMV disease. Although transplantation was 
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from EBV-positive donors to EBV-negative recipients in 11 
(65%) of the 17 cases, the incidence of post-transplant lym-
phoproliferative disorder (PTLD) was zero. Polyoma (BK) 
virus infection, the importance and treatment of which in 
kidney recipients has been recognized only in the last 10 
years,30,31 was not observed. 
Nonrenal Adverse Events 
One alemtuzumab-treated recipient developed insulin-
dependent diabetes mellitus after retransplantation that has 
improved but not fully reversed with spaced weaning of ta-
crolimus to every other day. This patient also had developed 
diabetes after the previous transplantation. A second alemtu-
zumab-treated recipient, who developed diabetes associated 
with rapid weight gain, is receiving dietary advice. 
Two patients, one each treated withATG and alemtu-
zumab, were diagnosed with autoimmune hemolytic anemia 
that was not associated with deterioration of renal function. 
This complication was successfully managed with a course of 
adrenal corticosteroids. Both patients are currently steroid-
free. The ATG-conditioned patient was switched from ta-
crolimus to cyclosporine, and then from cyclosporine to siroli-
mus, and remains on sirolimus monotherapy. The 
alemtuzumab-conditioned patient has been weaned to one 
dose every other day of tacrolimus. 
Growth 
The growth retardation associated with chronic immu-
nosuppression described 35 years ago32 and many times sub-
sequencly14 was avoided as shown in Figure 3 for the 16 
patients with current graft function. On the average, these 
recipients were below normal before transplantation, with 
mean age- and gender-adjusted height Z scores of -1.53 ± 
1.86. The current height Z score has improved to -0.74 ± 
1.46 for a mean gain of 0.79 ± 0.67. The weight Z score 
improved from -0.90 ::!: 1.79 to the present score of -0.28 ± 
1.63 for a gain of 0.62 ± 0.96. The improvement in both Z 
scores was most notable in the short-stature or light-weight 
recipients of young age. 
DISCUSSION 
The strategy applied in these patients was reminiscent 
of that employed in 1962 to. 1963 for 16 consecutive pediatric 
recipients of live donor kidneys at the University of Colorado. 
Recipient pretreatment with azathioprine had been shown to 
improve canine kidney allograft survival compared with sur-
vival with postoperative therapy only. Consequently, dailyaza-
thioprine in the pioneer patients was started 1 to 4 weeks33 
before transplantation, a far less effective pretreatment than 
the antibody infusion of the current recipients. Instead of 
tacrolimus, post-transplant monotherapy was with azathio-
prine, to which prednisone was added only to treat rejec-
tion.1,33 At the time of a 1966 report,34 12 of the 16 historical 
recipients were alive with functioning grafts after follow-ups 
of 21 to 36 months. Now, after 41.4 to 42.2 post-transplant 
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Figure 3. Height (Panel A) and weight (Panel B) for age and gender Z 
scores for the 16 patients who bear functioning grafts. Reference 
population data is from the 2000 Centers for Disease Control, growth 
data available online at www.cdc.gov/growthcharts. 
years, six still bear their original grafts, all but one with a 
normal serum creatinine. Moreover, four of the six have been 
off all immunosuppression for 5 to 21 years.35 
By 1964, the original strategy was modified in two ways 
in Colorado and worldwide.35 Because 15% to 20% of the 
rejections had proved to be irreversible, large doses of pred-
nisone were given from the time of operation instead of being 
added to azathioprine as needed. The second modification 
was de-emphasis or omission of pretreatment. These changes 
were carried forward after cyclosporine and tacrolimus be-
came available, using the new drugs as one component of 
multi-agent regimens. Reliable prevention of acute rejection 
resulted, as well as reduction in the use of steroids. 8-13 How-
ever, the drastic weaning from immunosuppression accom-
plished in the early cases was almost never accomplished. 
Efforts to improve the complex protocols were frustrated for 
many years because the mechanisms of organ engraftment, 
and the effect of immunosuppression on these mechanisms, 
were unknown. 
After donor leukocyte microchimerism was discovered 
in 1992 in our long-surviving kidney and liver recipients, 
including the survivors from the bellwether 1962 to 1963 
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pediatric renal series,36,37 it was concluded that exhaustion-
deletion of the antidonor response initiated by migration into 
the recipient of the graft's migratory passenger leukocytes is 
the seminal mechanism of alloengraftment and of acquired 
tolerance (reviewed17.37-40). It also was suggested that strong 
prophylactic post-transplant immunosuppression could nar-
row the one-time-only window of opportunity for efficient 
acute clonal deletionp·39 To avoid this, the therapeutic prin-
ciples employed in the cases reported here were proposed. 17,25 
The purposes of lymphoid depletion were to reduce the 
anticipated donor-specific clonal response into a more easily 
controllable and deletable range before arrival of the graft, and 
to permit the safe use of light post-transplant immunosup-
pression. Because of its relative freedom from infusion reac-
tions, greater potency, and longer effect,22.23,41 alemtuzumab 
is our· current preferred antilymphoid antibody. 
After the strategy was shown to be effective for adult 
renal transplantation,25-27 it was adopted in 2003 as the 
optimal standard of care for pediatric kidney recipients at the 
CHP. Spaced weaning was initiated later than in the adults 
and was stopped at every other day or 3 doses per week. 
Further spacing is not planned until the third post-transplant 
year unless specifically indicated. Complete immunosuppres-
sion discontinuance is not contemplated except for life-
threatening reasons, eg, an uncontrollable post-transplant 
lymphoproliferative disorder. Similar to the experience of 
1962 to 1963, normal growth patterns that are part of a happy 
childhood appear to have resumed in the current recipients 
while there has been a paucity of drug-associated complica-
tions (eg, drug-specific side effects, opportunistic infections, 
and virus-associated malignancies). The hemolytic anemia in 
two of our current patients also was a deja vu observation. 
Similar puzzling early hematologic abnormalities were seen in 
the historical recipients, and they were readily controlled by 
temporary treatment with steroids.1 
Although we emphasize that the kidney recipients re-
ported here. had a short follow-up to date (mean 22 months, 
range 16 to 31), the continued well-being of these patients is 
presaged by observations still being made of their analogous 
predecessors of 40 years ago. 
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